




Dr. Shaf Keshavjee

Chief Medical and Scientific Officer



Dr. Shaf Keshavjee serves as the Chief Medical and Scientific Officer for XOR Labs Toronto. Dr. Keshavjee has relentlessly pursued his vision of the place of EVLP in the organ transplant ecosystem since 2004. He was the Principal Investigator of the initial scientific work on the Toronto EVLP and the landmark study published in the NEJM. As Chief Scientific Officer, he ensures the essential physiology elements of the Toronto EVLP system is manifest in XOR's products.

He is currently the Surgeon-in-Chief and Program Medical Director of the Sprott Department of Surgery at the University Health Network, a professor in the Division of Thoracic Surgery and Institute of Biomaterials and Biomedical Engineering at the University of Toronto. Dr. Keshavjee's specific research interest is in lung injury related to transplantation. His current work involves the study of molecular diagnostics and gene therapy strategies to repair organs and to engineer superior organs for transplantation. Dr. Keshavjee has served on the board of directors of the International Society for Heart and Lung Transplantation, The Canadian Society of Transplantation and on the Governing Council of the American Association for Thoracic Surgery. He has also received two Queen Elizabeth II Diamond Jubilee Medals and was awarded the Order of Ontario and also received Canada's highest civilian honor with an appointment as an Officer of the Order of Canada. He is currently the Treasurer of the Board of Directors of the American Association for Thoracic Surgery, the most prestigious organization in the specialty. He has previously served as Director on the Board of the International Society for Heart and Lung Transplantation. He has published over 350 scholarly papers and received more than C\$10M in peer-reviewed grant funding, much of it related to EVLP. His full publication list is available [here](#).